Hidradenitis Suppurativa Wound Care

Sponsor
Wake Forest University Health Sciences (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04354012
Collaborator
(none)
5
1
1
7
0.7

Study Details

Study Description

Brief Summary

The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform [ovine forestomach], Hydrofera Blue [methylene blue and gentian violet], and Hypafix tape. a combination methylene blue, gentian violet, and ovine forestomach wound care product.

Condition or Disease Intervention/Treatment Phase
  • Combination Product: methylene blue, gentian violet, and ovine forestomach wound dressings
Phase 2

Detailed Description

Hidradenitis suppurativa (HS) is a chronic and debilitating inflammatory disease most frequently affecting the axilla, groin, and inframammary regions. Symptoms include nodules, abscesses, sinus tract formation, malodorous drainage, and scarring. These symptoms interfere with everyday activities, which can lead to social embarrassment and isolation. Patients with HS suffer psychological effects, such as increased levels of anxiety, depression, and loneliness, which impair quality of life.

Patients suffer with the burden of at home wound care for recurrent, draining nodules. Persistent lesions affect patients' lives by limiting their daily activities. Currently, patients are instructed to use gauze and tape to cover draining wounds, but this can be insufficient and difficult due to the nature and location of lesions associated with HS. Patients suffer with caring for their wounds, which can lead to frustration. Providing patients with a standard wound care regimen to take home can improve patients' quality of life and control of their disease. General recommendations for wound care in HS patients are limited. Improvements in the standard of care for wound management in HS are needed to aid patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
5 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Case seriesCase series
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Prospective Case Series on a Combination Methylene Blue, Gentian Violet, and Ovine Forestomach-derived Extracellular Matrix Dressing for Hidradenitis Suppurativa
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2023
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

methylene blue, gentian violet, and ovine forestomach wound dressings to HS lesions

Combination Product: methylene blue, gentian violet, and ovine forestomach wound dressings
Hydrofera Blue is an antibacterial foam dressing that contains methylene blue and gentian violet to manage wounds. This is a safe, non-cytotoxic product that can be worn for 7 days while not inhibiting growth factors. This products wicks bacteria into the foam and away from the wound surface using natural negative pressure through capillary flow. Endoform (ovine forestomach) is a natural dermal template used in all phases of wound healing. This product helps to stabilize, build, and organize tissue in acute and chronic wounds. Hypafix tape aids in stabilization of wound dressings. This productIt is easy to apply, skin friendly, and comfortable to use.

Outcome Measures

Primary Outcome Measures

  1. Wound Healing Time [Change from baseline to week 1]

    Assess the time for wound healing to occur using Endoform and Hydrofera Blue products.

  2. Wound Healing Time [Change from week 1 to week 2]

    Assess the time for wound healing to occur using Endoform and Hydrofera Blue products.

  3. Wound Healing Time [Change from week 2 to week 4]

    Assess the time for wound healing to occur using Endoform and Hydrofera Blue products.

  4. Wound Healing Time [Change from week 4 to week 8]

    Assess the time for wound healing to occur using Endoform and Hydrofera Blue products.

  5. Percent of Wound Healing [Measure from Baseline to week 8]

    Asses the percent healing that occurs over 8 weeks of follow-up using Endoform and Hydrofera Blue products

Secondary Outcome Measures

  1. Pain Assessment [Change from baseline to week 1]

    Assess changes in patient reported pain via Numerical Rating Scale of Pain (NRS) a scale using a number from 0 to 10 where 0 is no pain or hurt and 10 is the most or worst pain.

  2. Pain Assessment [Change from week1 to week 2]

    Assess changes in patient reported pain via Numerical Rating Scale of Pain (NRS) a scale using a number from 0 to 10 where 0 is no pain or hurt and 10 is the most or worst pain.

  3. Pain Assessment [Change from week 2 to week 4]

    Assess changes in patient reported pain via Numerical Rating Scale of Pain (NRS) a scale using a number from 0 to 10 where 0 is no pain or hurt and 10 is the most or worst pain.

  4. Pain Assessment [Change from week 4 to week 8]

    Assess changes in patient reported pain via Numerical Rating Scale of Pain (NRS) a scale using a number from 0 to 10 where 0 is no pain or hurt and 10 is the most or worst pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Individuals with hidradenitis suppurativa with non-healing wounds or draining abscesses/nodules

  • Individuals over 18 years of age

Exclusion Criteria:
  • Individuals younger than 18 years of age

  • Individuals without a diagnosis of HS

Contacts and Locations

Locations

Site City State Country Postal Code
1 Wake Forest Health Sciences Dermatology Winston-Salem North Carolina United States 27104

Sponsors and Collaborators

  • Wake Forest University Health Sciences

Investigators

  • Principal Investigator: Rita O Pichardo, MD, Wake Forest University Health Sciences

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wake Forest University Health Sciences
ClinicalTrials.gov Identifier:
NCT04354012
Other Study ID Numbers:
  • IRB00063673
First Posted:
Apr 21, 2020
Last Update Posted:
Jul 27, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2022